DUBLIN, Jan. 11, 2018 /PRNewswire/ -- Endo
International plc (NASDAQ: ENDP) ("Endo") today announced that its
subsidiary, Endo Pharmaceuticals Inc. ("EPI"), has received a grand
jury subpoena from the United
States Attorney's Office for the Southern District of
Florida seeking documents and
information relating to products containing oxymorphone.
The subpoena broadly requests documents including, among others,
those produced in past or pending lawsuits and those relating to
product safety and efficacy, overdoses, diversion, thefts,
overprescribing, abuse/misuse, dependency or tolerance, withdrawal,
addictiveness, adverse events and manipulation. The subpoena
also requests distribution and other third party agreements,
together with sales and marketing, training, financial,
compensation and corporate information, as well as documents
relating to interactions with various government agencies,
including the U.S. Food and Drug Administration, Drug Enforcement
Administration, Veterans Administration, Federal Trade Commission,
Department of Health & Human Services, Medicare and
Medicaid. Endo and EPI intend to be responsive to the
subpoena and cooperate with any related government
investigation.
In all circumstances, it is Endo's policy to comply with
applicable laws, rules, regulations and industry guidance governing
the sale and marketing of pharmaceutical products.
About Endo International plc
Endo International plc
(NASDAQ: ENDP) is a highly focused generics and specialty branded
pharmaceutical company delivering quality medicines to patients in
need through excellence in development, manufacturing and
commercialization. Endo has global headquarters in
Dublin, Ireland, and U.S.
headquarters in Malvern, PA. Learn more at www.endo.com.
Cautionary Note Regarding Forward-Looking
Statements
This press release contains "forward-looking
statements," including statements regarding a federal grand jury
subpoena. All forward-looking statements in this press
release reflect the Company's current analysis of information and
represent the Company's judgment only as of the date of this press
release. If underlying assumptions prove inaccurate or
unknown risks or uncertainties materialize, actual results could
vary materially from the Company's expectations. Risks and
uncertainties include, among other things, general industry and
market conditions; technological advances and patents attained by
competitors; challenges inherent in the research and development
and regulatory processes, including regulatory decisions, product
recalls, withdrawals and other unusual items; challenges related to
product marketing, such as the unpredictability of market
acceptance for new products and/or the acceptance of new
indications for such products; inconsistency of treatment results
among patients; potential difficulties in manufacturing; the
outcome of litigation, settlement discussions or other adverse
proceedings; general economic conditions; and governmental laws and
regulations affecting domestic and foreign operations. The
Company expressly disclaims any intent or obligation to update
these forward-looking statements except as required by law.
Additional information concerning these and other risk
factors can be found in the Company's periodic reports filed with
the U.S. Securities and Exchange Commission and in Canada on the System for Electronic Data
Analysis and Retrieval ("SEDAR"), including current reports on Form
8-K, quarterly reports on Form 10-Q and annual reports on Form
10-K.